Patent US2714044A successfully refreshed from Google Patents.
Patent US3474751A successfully refreshed from Google Patents.
US4940586A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Skin permeation enhancer compositions using sucrose esters
Assignee: Alza Corp
•
Filing: 1988-10-13
•
Granted: 1990-07-10
•
Expires: 2008-10-13
Abstract
Abstract A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with sucrose monolaurate or a mixture of sucrose esters of coconut fatty acids, which is predominantly sucrose monolaurate. Preferred embodiments of therapeutic systems for delivering the drug and the sucrose ester employ a matrix containing drug at a concentration above saturation.
Inventors
- 👤 Yu-Ling Cheng
- 👤 Robert M. Gale
- 👤 Edna Sugihara
- 👤 Harold F. Sanders
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 19:43
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K47/00; A61K47/06; A61K47/26; A61K9/7069; A61K9/7084
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
57 words
A composition of matter for application to skin to deliver a biologically active agent by permeation therethrough comprising, in combination: a biologically active agent and a permeation enhancing amount of a permeation enhancer consisting essentially of sucrose monolaurate mixed with sucrose esters of coconut fatty acids said composition being dispersed within a physiologically compatible matrix or carrier.
Claim 2
Dependent Claim
57 words
A composition of matter for application to skin to deliver a biologically active agent by permeation therethrough comprising, in combination: a biologically active agent and a permeation enhancing amount of a permeation enhancer consisting essentially of sucrose monolaurate mixed with sucrose esters of coconut fatty acids said composition being dispersed within a physiologically compatible matrix or carrier.
Claim 3
Dependent Claim
16 words
The composition of claim 1 wherein said agent and material are dispersed within a carrier therefor.
Claim 4
Dependent Claim
22 words
The composition of claim 2 wherein said agent is present in an amount in excess of its saturation concentration in the carrier.
Claim 5
Dependent Claim
71 words
A composition of matter for application to skin to deliver a biologically active agent by permeation therethrough comprising, in combination: a. a biologically active agent selected from the group consisting of progesterone, estradiol valerate, hydromorphone and levorphanol; and b. a permeation enhancing amount of a permeation enhancer consisting essentially of sucrose monolaurate mixed with sucrose esters of coconut fatty acids said compositions being dispersed within a physiologically compatible matrix or carrier.
Claim 6
Dependent Claim
71 words
A composition of matter for application to skin to deliver a biologically active agent by permeation therethrough comprising, in combination: a. a biologically active agent selected from the group consisting of progesterone, estradiol valerate, hydromorphone and levorphanol; and b. a permeation enhancing amount of a permeation enhancer consisting essentially of sucrose monolaurate mixed with sucrose esters of coconut fatty acids said compositions being dispersed within a physiologically compatible matrix or carrier.
Claim 7
Dependent Claim
26 words
The composition of claim 1 wherein said biologically active agent comprises a material selected from the group consisting of estradiol, hydrocortisone, ouabain, morphine, hydromorphone and methadone.
Claim 8
Dependent Claim
64 words
The composition of claim 1 wherein said biologically active agent comprises a material selected from the group consisting of scopolamine, isosorbide dinitrate, nitroglycerin, clonidine, cortisone, theophylline, phenylephrine, terbutaline, ephedrine, narcotine, quinidine, estradiol diacetate, pilocarpine, furosemide, tetracycline, insulin, chlorpheniramine sulfathiazides, propranolol, testosterone, norgestrel, lidocaine, morphinone dihydrocodeine, dihydromorphine, oxycodone, hydrocodone, codeine, norcodeine hydromorphine, normophine, norlevorphanol, dihydrothebaine, bromocrytine, guanabenz, salbutamol, oxprenolol, tetracaine, dibucaine, altenolol, pindolol and timolol.
References Cited (Backward Citations)
DE1001949B
Cited
US2893990A
Cited
US3527864A
Cited
US3472931A
Cited
US3598122A
Cited
US3598123A
Cited
US3598122B1
Cited
DE2241667A1
Cited
US3882243A
Cited
US3903256A
Cited
US3896238A
Cited
US3952099A
Cited
US4046886A
Cited
US4144317A
Cited
US4405616A
Cited
US4130643A
Cited
US4130667A
Cited
US4335115A
Cited
US4299826A
Cited
US4286592A
Cited
US4314557A
Cited
EP0057462A2
Cited
US4379454A
Cited
US4343798A
Cited
US4568343A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-07-09 | 1994-01-08 | 1994-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-07-09 | 1998-01-08 | 1998-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-07-09 | 2002-01-08 | 2002-07-10 | $7700.00 | Window Closed / Lapsed |